The synergistic effects of combined CTLA-4 mAb with CD73 mAb and combined PD-1 mAb with CD73 mAb immunotherapy have been observed in preclinical models of both breast cancer and colon cancer (24, 45, 68). This evidence concerns the gene NT5E and breast carcinoma.